Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, CA.
Division of Maternal-Fetal Medicine, The University of Utah School of Medicine, Salt Lake City, UT.
Am J Obstet Gynecol. 2023 Feb;228(2):217.e1-217.e14. doi: 10.1016/j.ajog.2022.08.015. Epub 2022 Aug 13.
Delayed cord clamping and umbilical cord milking provide placental transfusion to vigorous newborns. Delayed cord clamping in nonvigorous newborns may not be provided owing to a perceived need for immediate resuscitation. Umbilical cord milking is an alternative, as it can be performed more quickly than delayed cord clamping and may confer similar benefits.
We hypothesized that umbilical cord milking would reduce admission to the neonatal intensive care unit compared with early cord clamping in nonvigorous newborns born between 35 and 42 weeks' gestation.
This was a pragmatic cluster-randomized crossover trial of infants born at 35 to 42 weeks' gestation in 10 medical centers in 3 countries between January 2019 and May 2021. The centers were randomized to umbilical cord milking or early cord clamping for approximately 1 year and then crossed over for an additional year or until the required number of consented subjects was reached. Waiver of consent as obtained in all centers to implement the intervention. Infants were eligible if nonvigorous at birth (poor tone, pale color, or lack of breathing in the first 15 seconds after birth) and were assigned to umbilical cord milking or early cord clamping according to their birth hospital randomization assignment. The baseline characteristics and outcomes were collected following deferred informed consent. The primary outcome was admission to the neonatal intensive care unit for predefined criteria. The main safety outcome was hypoxic-ischemic encephalopathy. Data were analyzed by the intention-to-treat concept.
Among 16,234 screened newborns, 1780 were eligible (905 umbilical cord milking, 875 early cord clamping), and 1730 had primary outcome data for analysis (97% of eligible; 872 umbilical cord milking, 858 early cord clamping) either via informed consent (606 umbilical cord milking, 601 early cord clamping) or waiver of informed consent (266 umbilical cord milking, 257 early cord clamping). The difference in the frequency of neonatal intensive care unit admission using predefined criteria between the umbilical cord milking (23%) and early cord clamping (28%) groups did not reach statistical significance (modeled odds ratio, 0.69; 95% confidence interval, 0.41-1.14). Umbilical cord milking was associated with predefined secondary outcomes, including higher hemoglobin (modeled mean difference between umbilical cord milking and early cord clamping groups 0.68 g/dL, 95% confidence interval, 0.31-1.05), lower odds of abnormal 1-minute Apgar scores (Apgar ≤3, 30% vs 34%, crude odds ratio, 0.72; 95% confidence interval, 0.56-0.92); cardiorespiratory support at delivery (61% vs 71%, modeled odds ratio, 0.57; 95% confidence interval, 0.33-0.99), and therapeutic hypothermia (3% vs 4%, crude odds ratio, 0.57; 95% confidence interval, 0.33-0.99). Moderate-to-severe hypoxic-ischemic encephalopathy was significantly less common with umbilical cord milking (1% vs 3%, crude odds ratio, 0.48; 95% confidence interval, 0.24-0.96). No significant differences were observed for normal saline bolus, phototherapy, abnormal 5-minute Apgar scores (Apgar ≤6, 15.7% vs 18.8%, crude odds ratio, 0.81; 95% confidence interval, 0.62-1.06), or a serious adverse event composite of death before discharge.
Among nonvigorous infants born at 35 to 42 weeks' gestation, umbilical cord milking did not reduce neonatal intensive care unit admission for predefined criteria. However, infants in the umbilical cord milking arm had higher hemoglobin, received less delivery room cardiorespiratory support, had a lower incidence of moderate-to-severe hypoxic-ischemic encephalopathy, and received less therapeutic hypothermia. These data may provide the first randomized controlled trial evidence that umbilical cord milking in nonvigorous infants is feasible, safe and, superior to early cord clamping.
延迟脐带结扎和脐带挤奶为活力新生儿提供胎盘输血。由于需要立即进行复苏,非活力新生儿的延迟脐带结扎可能无法提供。脐带挤奶是一种替代方法,因为它可以比延迟脐带结扎更快地进行,并且可能具有相似的益处。
我们假设在 35 至 42 周胎龄的非活力新生儿中,与早期脐带结扎相比,脐带挤奶会减少入住新生儿重症监护病房的人数。
这是一项在 2019 年 1 月至 2021 年 5 月期间在 3 个国家的 10 家医疗中心进行的 35 至 42 周胎龄婴儿的实用集群随机交叉试验。这些中心被随机分配进行脐带挤奶或早期脐带结扎,大约 1 年,然后再进行 1 年或直到达到同意的受试者人数。所有中心都放弃了同意实施干预的规定。如果新生儿出生时无活力(肌张力差、肤色苍白或出生后 15 秒内无呼吸),则符合进行脐带挤奶或早期脐带结扎的条件,并根据其出生医院的随机分配进行分配。在获得延期知情同意后收集基线特征和结果。主要结局是入住新生儿重症监护病房的标准。主要安全性结局是缺氧缺血性脑病。数据分析采用意向治疗的概念。
在筛选出的 16234 名新生儿中,有 1780 名符合条件(905 名进行脐带挤奶,875 名进行早期脐带结扎),有 1730 名新生儿有主要结局数据进行分析(97%的符合条件;872 名进行脐带挤奶,858 名进行早期脐带结扎),要么通过知情同意(606 名进行脐带挤奶,601 名进行早期脐带结扎),要么放弃知情同意(266 名进行脐带挤奶,257 名进行早期脐带结扎)。使用预定义标准,脐带挤奶组(23%)和早期脐带结扎组(28%)的新生儿重症监护病房入住率差异无统计学意义(模型优势比,0.69;95%置信区间,0.41-1.14)。脐带挤奶与预定义次要结局相关,包括更高的血红蛋白(脐带挤奶组与早期脐带结扎组之间的模型平均差异为 0.68g/dL,95%置信区间为 0.31-1.05),较低的 1 分钟 Apgar 评分异常(Apgar ≤3,30% 与 34%,粗优势比,0.72;95%置信区间,0.56-0.92),分娩时的心肺支持(61% 与 71%,模型优势比,0.57;95%置信区间,0.33-0.99),以及治疗性低温治疗(3% 与 4%,粗优势比,0.57;95%置信区间,0.33-0.99)。与早期脐带结扎相比,中重度缺氧缺血性脑病明显较少(1%与 3%,粗优势比,0.48;95%置信区间,0.24-0.96)。未观察到生理盐水冲击、光疗、5 分钟 Apgar 评分异常(Apgar ≤6,15.7% 与 18.8%,粗优势比,0.81;95%置信区间,0.62-1.06)或死亡前出院的严重不良事件综合指标有显著差异。
在 35 至 42 周胎龄的非活力新生儿中,与早期脐带结扎相比,脐带挤奶并没有减少入住新生儿重症监护病房的人数。然而,脐带挤奶组的婴儿血红蛋白较高,分娩时心肺支持较少,中重度缺氧缺血性脑病发生率较低,接受治疗性低温治疗的比例较低。这些数据可能首次提供了随机对照试验证据,证明在非活力新生儿中进行脐带挤奶是可行、安全的,而且优于早期脐带结扎。